Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

PITTSBURGH — Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue ...

A research team has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Should you invest in Bicara Therapeutics Inc? Click for more on BCAX's promising cancer treatment, but proceed with caution ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining ...

Fecal microbiota transplantation has significantly improved progression-free survival in patients with metastatic renal cell ...

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on IO Biotech (IOBT – Research Report), retaining the price target of ...

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...

Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, ...

NuCana (NCNA) announced that initial data from the ongoing Phase 1b/2 modular study investigating NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...